In addition to their hypoglycemic action due to the promotion of urinary glucose excretion, sodium-glucose cotransporter 2 (SGLT2) inhibitors provide multiple clinical benefits, including prevention of heart failure and preservation of renal function [1-8]. Here, SLC5A2 is linked to heart failure.